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Is the polymorphism in the promoter region of CYP17 gene a risk factor for
prostate cancer in Polish population?
Monika Gos1, Ma∏gorzata Sadowska2, Marek Grzegrzó∏ka3,
Tomasz Demkow2, Przemys∏aw Janik1
I n t r o d u c t i o n.  Prostate cancer is one of the most commonly diagnosed tumors in Poland especially in men over 70
years of age. In the year 2000, the incidence rates were about 9/100 000 and 252/100 000 for men under and over 70 years,
respectively. Generally, age is considered the most important risk factor for prostate cancer etiology. It is also known that
androgen metabolism can influence its development. Cytochrome P450c17α plays a special role in the biosynthesis of
steroid hormones and alterations in the gene encoding this protein (CYP17) can, probably, alter the production of sex-
gormones.
M a t e r i a l s  a n d  m e t h o d s.  A single-nucleotide polymorphism (T→C) in the promoter of CYP17 gene was examined in
patients with prostate cancer and age-matched controls. The DNA was extracted from blood spots or blood samples prepared
for PSA analysis. The examined region of CYP17 gene was amplified and the product was digested overnight with MspAI
enzyme. The resulted fragments were analyzed by electrophoresis in agarose gel with ethidium bromide.
Re s u l t s.  We were able to find three possible variants in the promoter region of CYP17 gene – TT, TC and CC, however their
prevalence did not differ between the examined groups. The groups were divided according to age (<70 and ≥70), and it was
found that the CC genotype was more common among younger patients, as compared to the adequate control group.
C o n c l u s i o n.  We conclude that the CC variant can be a risk factor for tumor development, especially in men before their
seventies, although further studies are necessary to confirm this hypothesis.
Czy polimorfizm w regionie promotorowym genu CYP17 mo˝e byç czynnikiem ryzyka
w powstawaniu raka stercza w polskiej populacji?
W s t ´ p.  Rak stercza jest jednym z najcz´Êciej diagnozowanych nowotworów w Polsce. Szczególnie cz´sto wyst´puje on
u m´˝czyzn po siedemdziesiàtym roku ˝ycia. Wiek jest wymieniany jako jeden z g∏ównych czynników sprzyjajàcych powstawaniu
raka prostaty. W roku 2000 wspó∏czynniki zapadalnoÊci dla m´˝czyzn przed siedemdziesiàtym rokiem ˝ycia i starszych
wynosi∏y odpowiednio: 9/100 000 i 252/100 000. Dla rozwoju tego nowotworu du˝e znaczenie ma równie˝ metabolizm
androgenów. Szczególnà rol´ w przemianach cholesterolu do hormonów sterydowych odgrywa cytochrom P450c17α,
w zwiàzku z czym zmiany w genie kodujàcym to bia∏ko (CYP17) mogà wp∏ywaç na syntez´ hormonów p∏ciowych.
M a t e r i a ∏ y  i m e t o d y.  U pacjentów z rakiem stercza oraz odpowiednio dopasowanych pod wzgl´dem wieku kontrolach
przeprowadzono analiz´ wyst´powania jednonukleotydowego polimorfizmu (T→C) w regionie promotorowym genu CYP17.
DNA izolowano z plam krwi lub próbek krwi przygotowywanych do badania poziomu PSA. Badany region by∏ powielany,
a nast´pnie produkt reakcji poddawano ca∏onocnej inkubacji z enzymem restrykcyjnym MspAI w temperaturze 37°C.
Otrzymane fragmenty rozdzielano elektroforetycznie w ˝elu agarozowym z bromkiem etydyny.
W y n i k i.  Znaleziono trzy mo˝liwe genotypy: TT, TC i CC, które mogà wyst´powaç w regionie promotorowym genu CYP17,
jednak˝e cz´stoÊç ich wyst´powania nie ró˝ni∏a si´ w badanych grupach. Badana populacja zosta∏a wi´c podzielona na
dwie grupy wiekowe: <70 i ≥70 roku ˝ycia, co pozwoli∏o na stwierdzenie, ˝e genotyp CC wyst´puje cz´Êciej wÊród pacjentów
przed 70 rokiem ˝ycia, w porównaniu do odpowiedniej grupy kontrolnej.
W n i o s k i.  Sugerujemy wi´c, ˝e wariant CC mo˝e stanowiç czynnik sprzyjajàcy pojawieniu si´ nowotworu u m´˝czyzn
przed siedemdziesiàtym rokiem ˝ycia. JednoczeÊnie konieczne sà dalsze badania w celu potwierdzenia tej hipotezy.
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Introduction
Prostate cancer, besides lung and colon cancer, is the
most common tumor in Polish male population, especially
over 70 years of age. Every year about 4000 new cases
are diagnosed, however this disease is rather rare among
men below fifty years of age [1]. The mortality rate from
prostate cancer tended to grow during the previous
decades and in the early nineties amounted to
10.1/100 000. This phenomenon could have been brought
on by better diagnostic methods (USG, test for PSA con-
centration in serum) as well as by increased patient
awareness [2].
Prostate cancer is a multifactorial disease, which
means that it can be provoked by environmental and
genetic factors. It seems that the most important of these
is age; 80% of all cases are diagnosed in men over 65
years [3]. Also, ethnicity is suggested to affect prostate
cancer occurrence – the disease is more common in Afro-
Americans, as compared to Caucasians and Asians, who
present the lowest incidence of this malignancy [4].
Another factor involved in prostate cancer etiology is
diet, especially excessive intake of fatty acids can provoke
tumor development [5].
Epidemiology indicates that the risk of prostate
cancer is about 5-11 times higher in families with two or
more cases of the disease among first-degree relatives,
however it seems that only about 10% of all prostate
cancers are hereditary [3]. Several loci were identified
which co segregate with prostate cancer in families and
among them were: HPC1, PCAP, CAPB on chromosome
1 (1q24-q25, 1q42-q43, 1p36 respectively), HPC2/ELAC2
– chromosome 17 (17p11), HPC20 – chromosome 20
(20q13) and HPCX – chromosome X (Xq27-q28) [6].
These results are not unambiguous, probably due to the
multifactorial etiology of the prostate cancer.
About 90% of prostate cancers are sporadic cases
that are probably caused by the combination of envi-
ronmental factors and several mutations with low
penetrance. It has been suggested that attention should be
paid to the androgen metabolism, because elevated levels
of steroid hormones, especially testosterone, can be
associated with prostate cancer development and pro-
gression. Although some studies have failed to find such
a correlation it cannot be excluded that mutations in the
genes encoding key enzymes of steroid metabolism lead
to higher risk of prostate cancer.
The precursor for all steroid hormones is cholesterol,
which is metabolized to progesterone through cutting off
its side chain and oxidation of hydroxylic group from C-3.
This metabolite can be used as the substrate for
glucocorticoid, mineralocorticoid or sex hormone
synthesis. In case of the sex hormones, progesterone is
converted to 17α-hydroxyprogesteron by hydroxylation
and then to androstendione by lysis reaction. These two
steps are catalyzed by cytochrome P450c17α, which
mediates both activities: steroid 17α-hydroxylase and
17, 20-lyase. The product of these reactions can be tran-
sformed to either testosterone or estron.
Cytochrome P450c17α is encoded by human CYP17
gene, which has been localized in chromosome 10
(10q24.3). A single base-pair change (T→C) in the
promoter region of this gene has been identified and it
was suggested that it leads to creation of additional Sp-1
binding site and consequently higher transcription rate
[7]. The aim of our work was to examine the possibility
that the polymorphism in the promoter region of CYP17
gene correlates with increased risk of prostate cancer in
Polish male population and whether it can be used as
a genetic marker of this malignancy.
Material and methods
Probands (71; mean age 69.4±7.6 years) included in this
examination were patients of the Clinic of Oncological Urology
of the Maria Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology in Warsaw. Diagnosis was set after prostate
gland biopsy. The control group consisted of men (117; mean
age 61.9±10.8 years) with no previous history of prostate cancer.
Among them were patients of the Institute of Cardiology, the
Maria Sklodowska-Curie Memorial Cancer Center and Institute
of Oncology and patients from one of the outpatient clinics in
Warsaw.
Blood for the DNA extraction was collected on IsoCode
Stix blots or blotting papers used for standard screening analysis
(both Schleicher&Schuell) and also from the blood samples
prepared for PSA determination. DNA from IsoCode Stix blots
was extracted according to manufacturer instruction (S&S
IsoCode® Card/Stix Protocol). SherlockAX or Mini Blood Kits for
DNA Isolation (A&A Biotechnology) were used for other
samples.
The polymorphism in the promoter region of CYP17
gene was identified using PCR/RFLP technique. The
specific fragment of 419bp was amplified with the following
primers: CYP17F 5`-cattcgcacctctggagtc-3` and CYP17R 5`-
ggctcttggggtacttg-3` (IBB, PAN). The reaction mixture (total
volume 25 µl) apart from DNA, contained 15pmol of each
primer, all deoxynucleotide triphosphates (final concentration
250 µM, Amersham), PCR buffer with magnesium (Sigma) and
1U of RedTaq Polymerase (Sigma). The reactions were held in
GeneAmp PCR System 9600 (Perkin-Elmer) in following
conditions: initial denaturation – 5 min at 95°C, then 35 cycles
composed of 95°C for 30 sec, 59°C for 30 sec and 72°C for 35 sec,
and finally elongation step at 72°C for 10 minutes. The PCR
products were digested overnight with MspA1 I restriction
enzyme (New England Biolabs) according to manufacturers
instructions. The resulting fragments were analyzed in 2%
agarose gel (Sigma) stained with ethidium-bromide (Sigma).
Statistical analysis was conducted with Microsoft Excel 2000
(mean values and standard deviations) and SPSS package v.8.0
for Windows 98 (frequencies and statistical significance).
Results
As could be expected three possible genotypes were
found in our examined population (see Figure 1),
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however their frequencies did not differ between the
control and proband groups (Table I). The prevalence of
alleles was also similar in both groups (Table II).
Therefore, we divided our patient population according to
age, where the cut-off value was the mean age in
probands group. We observed higher frequency of the
CC genotype and the C allele among patients below 70
years of age (31.2% and 0.48 respectively), as compared
to an adequate control group (17.3% and 0.37), however
the results were not statistically significant. A reversed
situation was observed in the elderly group – the CC
genotype and the C allele were more common in control
group (respectively 30.6% and 0.54), than among prostate
cancer patients (12.8% and 0.40). The outcome did not
reach statistical significance. We also observed differences
in the genotypes and the alleles frequencies in the control
and the proband groups divided according to age (Tables
I and II). The difference in the alleles distribution among
controls was statistically significant (p=0.015).
Discusion
It is generally known that cytochrome P450c17α plays
a key role in steroid metabolism and for this reason any
genetic alterations in CYP17 gene can affect sex-hormone
synthesis. A single nucleotide polymorphism (T→C) in
the promoter region was described and suggested to
create an additional Sp1-binding site similar to this
observed in ε-globine gene. Although in vitro examination
of recombinant Sp-1 binding to changed sequence in gel
mobility shift assay did not support this hypothesis, it
cannot be excluded that the C variant correlates with
altered gene expression and modification in androgen
metabolism [8].
The frequency of the CC genotype in Polish
population (21.4%) according to our study is slightly
higher than its prevalence observed in other white
populations such as Swedish – 16% (9) or American
Whites – 14% [10]. In the Japanese and related po-
pulations, which have the incidence of prostate cancer
about 5 times lower, the frequency of CC variant is
estimated for about 26% [11]. Consequently the genotype
should have a lower frequency in black populations, which
have the highest worldwide occurrence of prostate cancer
calculated as 2 times higher than in white populations.
Such difference was not found when African American or
Nigerian populations were compared with a White-
American group [12].
We were not able to find a correlation between any
variant of CYP17 gene and prostate cancer risk and
therefore we divided our groups according to age (<70
and ≥70). The occurrence of prostate cancer in these
groups was different in Polish population. The incidence
and mortality rates were as follows: 9/100 000 and
4.5/100 000 for men before their seventies and
252/100 000 and 215/100 000 – men 70 years of age and
older (dr J. Lissowska, personal communication). We
observed slight differences between probands and control
groups divided according to age. Therefore, it seems that
the CC genotype can correlate with prostate cancer
occurrence in Polish men below 70 years of age. Contrary
results obtained in the elder group can be caused by
a non-homogenous control population. It is possible that
some of these men have developed benign prostatic
hyperplasia, which is also suspected to depend on
androgen metabolism.
Conflicting results concerning the correlation
between CYP17 variants and prostate cancer were already
reported. In Austrian population the CC genotype was
more common among patients with prostate cancer
(23.8%) than in the control group (9.5%) and the result
was statistically significant (p=0.03; [13]). The same
tendency was also observed among Americans. In three
Figure 1. Results of analysis of T→C polymorphism in the promoter
region in CYP17 gene.
DNA was amplified and the resulted fragment was digested with
MspA1 I enzyme. The presence of C nucleotide, which is supposed to
be a risk factor for prostate cancer development, creates a cleavage
site for MspA1 I restriction enzyme (295 and 124bp), which is not
observed in case of T allele (419bp)
Table I. Frequencies of genotypes in examined population
group genotype
TT (a1/a1) TC (a1/a2) CC (a2/a2)
controls – all 36.8% (43) 41.8% (49) 21.4% (25)
probands – all 33.8% (24) 45.1% (32) 21.1% (15)
controls < 70 43.2% (35) 39.0% (32) 17.3% (14)
probands < 70 34.4% (11) 34.4% (11) 31.2% (10)
controls ≥ 70 22.2% (8) 47.2% (17) 30.6% (11)
probands ≥ 70 33.3% (13) 53.9% (21) 12.8% (5)
Table II. Frequencies of alleles in examined population
group allel
T (a1) C (a2)
controls – all 0.58 0.42
probands – all 0.56 0.44
controls < 70 0.63 0.37
probands < 70 0.52 0.48
controls ≥ 70 0.46 0.54
probands ≥ 70 0.60 0.40
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independent investigations from North California,
Bethesda (majority of participants were of Caucasian
origin) and Baltimore (African American population)
the CC variant had higher frequency in patients with
prostate cancer (14%, 18% and 15%, respectively)
as compared to the controls (11%, 14% and 9%,
respectively). The analysis made for the first and third
center revealed statistically significant results [3, 10, 12].
Moreover, examination according to age was performed
in the North Carolina and Bethesda centers. Men younger
than 65 years (North Carolina) carrying at least one C
allele were more susceptible to prostate cancer
development (p=0.03, OR-2.3; [3]). Also in the Japanese
population the CC genotype was more prevalent among
men with prostate cancer (19%) compared to controls
(14%). When the examined group was divided acc. to
age (cut-off value 72 years) such a correlation was not
found in the elder population, however it was even
stronger in the group below 72 years (p=0.04, OR-4.02
[14]).
Contradicting results were reported in another
investigation performed on Japanese men. The CC
variant, which is supposed to correlate with prostate
cancer, was more frequent among controls (28%) than
in prostate cancer patients (18%) and the results
were statistically significant (p=0.022; [11]) as in the
Swedish population, where the TT genotype was more
frequent in patients (39%) than among controls (29%;
p=0,04; [9]).
Although these results are contradictory it seems
that the T→C polymorphism in the promoter region of
CYP17 does affect sex-hormone metabolism. It has been
shown that the mutated allele is correlated with higher
progesterone and estrogen levels. In women progesterone
level on 22nd day and estrogen (E2) levels on the 11th and
22nd day of the menstrual cycle were respectively about
30%, 57% and 28% higher in premenopausal subjects
carrying two C alleles as compared to subjects homo-
genous with the T variant (p values 0.04, 0.04 and 0.06,
respectively). This can be a risk factor for breast cancer
development [7]. Such relationships between the genotype
and testosterone, estradiol and dihydrotestosterone serum
levels were not found [15, 16].
CYP17 is not the only gene, the genetic alterations of
CYP17 can influence androgen metabolism. Also
mutations in SRD5A2 gene encoding 5α-reductase type II,
which catalyzes the conversion of testosterone to its more
active form – dihydrotestosterone (DHT), can affect the
level of circulating sex-hormones [15, 16]. Furthermore,
two polymorphic sites with variable number of tri-
nucleotide repeats (CAG and GGN) were found in the
gene for nuclear androgen receptor on chromosome X.
Several studies have confirmed that shorter variants
correlated with enhanced prostate cancer risk and poor
prognosis of the disease [17, 18].
It seems that polymorphism of the CYP17 gene can
influence prostate cancer development especially in men
below 70 years of age (Polish population), however
further studies are necessary to obtain statistically
significant results. Also the analysis of polymorphisms in
other genes correlating with steroid hormones metabolism
and their signaling pathways might help to provide
evidence for the genetic basis of sporadic prostate cancer
incidence.
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